Related Experiment Videos
[SERM and SARM]
Hiroshi Kaji1, Toshitsugu Sugimoto
1Division of Endocrinology / Metabolism, Neurology, Hematology / Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine.
Clinical Calcium
|March 19, 2005
Summary
Selective estrogen receptor modulators (SERM) offer tissue-specific effects, with raloxifene reducing vertebral fractures. Selective androgen receptor modulators (SARM) are now being studied for osteoporosis treatment.
Area of Science:
- Endocrinology
- Pharmacology
- Bone Biology
Context:
- Estrogen therapy presents unfavorable effects.
- Selective estrogen receptor modulators (SERM) have been developed to provide tissue-specific estrogen agonist and antagonist actions.
- Raloxifene, a SERM, demonstrates efficacy in reducing vertebral fracture risk, comparable to bisphosphonates.
Purpose:
- To explore the development and potential of selective androgen receptor modulators (SARM) as a therapeutic strategy for osteoporosis.
- To leverage the tissue-selective modulation approach, previously successful with SERMs, for androgen signaling in bone.
Summary:
- Raloxifene exemplifies the success of tissue-selective receptor modulation in managing bone health.
- The principles guiding SERM development are being applied to create SARMs.
- Research is ongoing to investigate SARMs for osteoporosis treatment, aiming for similar therapeutic benefits with potentially improved safety profiles.
Impact:
- Advances in osteoporosis treatment through targeted therapies.
- Potential for novel therapeutic agents that modulate hormone receptor activity selectively.
- Improved management of bone loss and fracture prevention.